Ordering workflow
How to place an office-use order for your clinic
Whether your practice can order compounded stock depends on three things: what you are ordering, which state you practise in, and whether it comes from a state-licensed 503A pharmacy or from a facility registered with FDA as an outsourcing facility under section 503B. The outsourcing-facility route is the one that generally works — but it is not a national permission. In every state we have read from primary sources, the facility must also hold that state’s own credential, and what your practice must hold depends on your entity type and on whether you administer the stock or dispense it.
What actually decides whether you can order office stock?
Three things, and they are independent of each other.
What you are ordering decides which legal pathway the preparation can travel on at all. Where you practise decides whether your state's pharmacy rules permit a non-patient-specific supply to a prescriber, and the answer differs sharply between states that look similar. Which kind of supplier fills it decides whether federal law was ever satisfied in the first place.
Federal law sets the floor for the third question: § 353a's exemption is written around "an identified individual patient," and office stock is by definition not patient-specific, so the federal default for a state-licensed 503A pharmacy is that office-use distribution sits outside it, whatever your state rule says. Why that is, and what follows from it, is the subject of 503A vs 503B rather than of this page — here it matters only because it decides which supplier can fill your order.
What are the two routes, and how do they differ?
There are two ways compounded product reaches a practice, and only one of them is built for stock on a shelf.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A pharmacy licensed by a state board of pharmacy | A facility registered with FDA as an outsourcing facility under section 503B, which also holds the state licences required where it ships |
| Federal default for non-patient-specific supply | Outside the § 353a exemption — the exemption is written around an identified individual patient | Contemplated. Several states that bar a state-licensed pharmacy from supplying office stock write an express exception for outsourcing facilities |
| What you order against | A named patient, on a prescription | Your practice's account, with no patient named |
| What limits the menu | The 503A bulk-substance eligibility test | If compounded from a bulk drug substance, that substance must be on the 503B bulks list, or the drug must be on FDA's shortage list at the time of compounding, distribution and dispensing |
| Where state law still bites | Every state; several prohibit human office use outright | Non-resident registration, licensure and labelling rules still apply in each state shipped into |
Georgia's rule is the clearest statement of the split. After prohibiting office-use distribution for human practitioners, it adds: "This subsection shall not affect 503b outsourcing facilities ability to provide non-patient specific compounded preparations for office use by a practitioner." Illinois writes the same split as a prohibition, which is the order the rule itself uses: "Sterile compounding for office use is prohibited unless the pharmacy is in full compliance with 21 USC 353b, including becoming registered as an outsourcing facility and licensed as a wholesale drug distributor." Ohio's guidance for prescriber practices names possession of compounded preparations supplied by an Ohio-licensed outsourcing facility as an activity that does not trigger practice licensure. Three different rule structures, all routing office stock the same way.
What your state requires to receive 503B office stock
Everything above answers the supply question: may a pharmacy ship you non-patient-specific stock? This is the other half, it is the half the industry gets wrong, and it has two parts.
The 503B route is open in every state we have read from primary sources — and in every one of them the outsourcing facility must also hold that state's own credential. FDA registration on its own is never the whole answer. Section 353b is an exemption from federal requirements. It preempts no state licensing scheme, and it regulates the facility rather than the facility's customer, which is why what your own practice must hold is a pure question of state law. A facility fully compliant with § 353b and unlicensed in your state is not compliant. It is federally clean and state-exposed.
So the pre-order check has two steps, not one: verify the facility's FDA registration, then verify its credential in your state — and settle what your own practice needs before the first box arrives.
Administer or dispense? Decide before you order
This is the distinction that decides your practice's exposure, and almost no supplier page draws it. Holding stock to administer in the office is the clean case nearly everywhere. Handing a patient a vial to take home is dispensing, and in almost every state we read it triggers a registration, a permit, or a bar.
North Carolina puts the heaviest version of it on your building: 21 NCAC 46 .1703(c) requires that all drugs dispensed by a nurse practitioner or physician assistant "must be dispensed from a place holding a current pharmacy permit from the Board." Florida bars a registered dispensing practitioner from dispensing a Schedule II or Schedule III controlled substance at all, while settling the threshold in the other direction by statute — "The administration shall not be considered dispensing." Louisiana and Arizona attach a dispensing-practitioner registration, New York caps prescriber dispensing at a 72-hour supply and New Jersey at seven days, and Colorado's authority to dispense collides with a section reserving dispensing to registered outlets.
Say "administer in office," and mean it.
Does your own practice need its own permit?
Only the case where an individual practitioner buys under their own licence is clean, and only in some states. Where a receiving-side permit exists, it is keyed to your entity type rather than to the drug.
| State | What triggers it | What you need |
|---|---|---|
| Florida | The business entity buys the drugs. Purchase by a licensed practitioner under their own licence is expressly carved out | A health care clinic establishment permit under Fla. Stat. § 499.01(1)(r) — not a pharmacy permit, and not the similarly named AHCA clinic licence |
| California | You are a nonprofit or free clinic (§ 4180), or a surgical clinic, accredited outpatient setting or Medicare-certified ambulatory surgical centre (§ 4190). A physician's own office is exempt | A board clinic licence per location, with a professional director and a consulting pharmacist visiting at least quarterly |
| Ohio | The prescriber practice holds dangerous drugs at the practice location | A terminal distributor of dangerous drugs licence. Board guidance carves out possession of preparations supplied by an Ohio-licensed outsourcing facility as lower-risk |
Elsewhere in the states we read, no receiving-practice permit was identified — which is not the same as establishing that none exists. Where a state page says "none identified," read it that way. The Ohio licence category, and what its Board says changes once a practice does anything to a preparation rather than merely holding it, is defined at terminal distributor of dangerous drugs.
Check the right agency, or you will find nothing
In some states the facility's credential is not issued by the board of pharmacy at all. A reader who checks the board finds nothing and concludes, wrongly, that no licence is required.
- North Carolina — the Department of Agriculture & Consumer Services, $1,000 a year under G.S. 106-140.1. The word "outsourcing" appears nowhere in the Board of Pharmacy's rules.
- Texas — the Department of State Health Services. The pharmacy board's rules master file contains no occurrence of "503A", "503B", "353a" or "outsourcing facilit" at all.
- Louisiana — the Board of Drug and Device Distributors, a separate agency from the Board of Pharmacy, plus a Board of Pharmacy controlled-substance licence if the product is scheduled.
Scheduled stock changes the answer again
Never assume that scheduled office stock follows the same rules as everything else on the shelf. In New Jersey and Louisiana a state controlled-substance registration is required for each physical location the moment scheduled product sits on site — a three-site practice needs three. New Jersey's exemption for a prescribe-only office collapses by its own terms: it covers an office where substances are prescribed "provided that no such substances are administered, delivered, or otherwise dispensed, and no such substances are contained in such office."
How does an outsourcing-facility order actually work?
The sequence below is the general shape of the transaction. Each step exists because a rule somewhere requires it, and each is a place where a supplier can be checked.
- Account setup. You open an account with the facility as a practice, not a patient file. The counterparty is the licensed prescriber, not the business entity — the office-use provisions we read name "a practitioner," or "practitioners authorized by law to prescribe drugs," or the same idea in local wording. None of them describes a company buying inventory.
- Credential verification. Your NPI, your state licence, and a DEA registration where the preparation is scheduled. Supplier-side credential duties are written into state pharmacy rules directly: Arizona requires a non-resident pharmacy to maintain a copy of each Arizona purchaser's current licence, producible within two business days; Texas conditions office-use distribution on a written agreement with the practitioner.
- Formulary selection. This is where most of the surprises live. Where a preparation is compounded from a bulk drug substance, FDA's position is that an outsourcing facility may not use that substance unless it appears on the 503B bulks list or the resulting drug is on FDA's shortage list at the time of compounding, distribution and dispensing. The published 503B bulks list is short and every entry on it is topical or oral. A supplier who cannot tell you which pathway a specific preparation sits on has not done the work.
What happens at the order itself, and on delivery?
- The order. No patient names, because that is what makes it office use. Illinois defines the term precisely, and the definition excludes the thing people confuse it with: "'Office use' does not include a pharmacy's delivery of a compounded drug to a prescribing practitioner's office pursuant to a valid patient-specific prescription."
- Receipt and lot documentation. Check the container against the label the law requires. New York requires outsourcing-facility product to bear "the statement that the drug is not for resale, and the statement 'Office Use Only'." Illinois requires "For Office Use Only Not for Resale" on every office-use container, alongside the pharmacy's lot number and beyond-use date. Texas requires "For Institutional or Office Use Only--Not for Resale." Record the lot number and the beyond-use date on arrival, before the box goes in the fridge.
Those two legends are worth knowing by sight, because a container that should carry one and does not is the cheapest compliance signal available to you. They are also state-specific rather than universal: the near-identical legend Florida once required was repealed on 9 April 2025, so the presence or absence of a legend tells you about the state the product was shipped under, not about the product.
What documentation should the practice keep?
Be careful about whose duty is whose. The retention periods written into the compounding rules we read run to the pharmacy, not to you — Illinois five years, Texas two years kept separately from prescription records, Arizona seven years. Your own obligations come from your licensing board's rules, which sit outside the pharmacy code and were not part of this research.
What is clearly a practice-side question is whether holding the stock changes your own licensure position. Ohio handles it that way: possessing dangerous drugs at a practice location raises a terminal distributor licensure question, and the Board's guidance for prescribers engaged in compounding says plainly that "preparation of such medications in advance of administration requires licensure and compliance with the Board's compounding rules."
A defensible file holds four things: the order and invoice, the container label showing lot and beyond-use date, evidence of the supplier's licence or registration, and a record tying each unit administered to the patient who received it. No rule among the states reviewed here imposes that last one uniformly on human practice — but Georgia requires exactly that charting in its veterinary channel, which is a reasonable floor to hold yourself to.
Which bucket is your state in, and why does it change the order?
Whether your state permits this at all is answered in full — verbatim rule text, citations, and what each review could not establish — in the state-by-state office-use guide. This page does not restate it. A verdict table that lives in five places is a table that goes stale in four of them, and the guide is the one that is maintained.
What the order depends on is only which bucket your state falls in, because that decides which of the two routes above is actually open to you:
- No 503A office-use lane at all. The order goes to an outsourcing facility, or it becomes patient-specific fulfilment. There is no third option to negotiate for.
- A lane that is conditioned or contested. Read the condition before you rely on it. Several are written as a pass-through to federal law, which hands the question straight back to § 353a and its identified-patient requirement.
- A lane that is open with operational conditions attached. The order itself is fine; what bites is the detail — sterile versus non-sterile, quantity caps, a mandatory label legend, and record duties that run to the supplier and sometimes to you.
The buckets are not stable over time. Arizona's office-use permission runs through 4 September 2026 and becomes veterinary-only from 5 September 2026, and both California's and Florida's governing provisions were repealed during 2025. Any supplier quoting a position from before those dates is quoting a rule that no longer exists — which is the next section.
What will the guide not tell you?
Two things, and both are where the industry's summaries go wrong. A state saying "permitted, consistent with federal law" has not given you a federal answer — it has handed the question back to § 353a, which requires an identified patient. And the mirror image also exists: a state whose pharmacy rules attach no federal condition at all has told you something true about that state and nothing at all about the FDCA. The federal framework behind all of it is in 503A vs 503B.
What should make you walk away from a supplier?
The failure modes are consistent, and most of them are visible before you place an order.
A supplier who ships office stock without asking for your NPI and state licence is skipping a step several states impose on suppliers by rule. A supplier who answers a legal question with a summary rather than a citation cannot be checked, which is the point of the summary. A supplier still citing California's old compounding regulation is citing a section repealed on 1 October 2025 — that section number now governs personnel training. A supplier citing Florida's old office-use label legend is citing a provision repealed on 9 April 2025.
Two phrasings should end the conversation on their own. "FDA-approved pharmacy," or any variant, describes something that does not exist; FDA does not approve or licence pharmacies, and the accurate description of an outsourcing facility is that it is registered with FDA under section 503B. And "office use is legal," said without naming a state, is not a claim anyone can stand behind — across every state we read, the answer is genuinely different in almost every one.
The verification sequence behind all of this — what is checkable on a public record without the supplier, what you have to ask for, and the questions worth sending verbatim — is set out in how to vet a compounding pharmacy.
A third answer is softer, and just as empty: a supplier who says only that they are compliant with USP, naming no chapter and no state. Adoption is version-dated and staggered, so the checkable version of that claim names the chapter and the board that adopted it — and in a state running a transition, a pharmacy may lawfully be working to a much older edition than the one you assumed. What to ask instead is on the glossary pages for <795>, <797> and <800>.
What sits either side of this page?
An account, before any of it, and a wider ordering workflow around it.
This page is about one transaction: what an office-use order carries and what comes back. It deliberately does not walk through becoming a customer of a pharmacy in the first place — that sequence, and the order the documents are asked for in, is at opening an account with a compounding pharmacy. Nor does it cover the other ways a clinic orders; office use is one of them, and the full set is mapped at how clinics order compounded medications.
Where does USPeptideRx fit in this?
We are a procurement layer, not a pharmacy. USPeptideRx verifies your credentials once, then routes orders to licensed 503A pharmacies and to facilities registered with FDA as outsourcing facilities under section 503B, depending on which pathway the preparation and your state actually allow. That routing decision is the work, and it is the part clinics most often get wrong on their own — usually by opening an account with whoever answered the phone and inheriting their compliance posture.
If you want your state, your practice type and your preparation list mapped against the two routes before you order anything, you can apply for an account.